Table 1

Study Participants
Patient ID Time
Gender Status ART CDA* CDA* VL+ HIV+ Time Tx Ag69e
HIV Control (n = 9) 204 F Control N/A 730 327 N/A N/A N/A 54
206 F Control N/A 510 275 N/A N/A N/A 69
213 F Control N/A 1021 382 N/A N/A N/A 43
214 F Control N/A 1559 1294 N/A N/A N/A 36
215 M Control N/A 380 290 N/A N/A N/A 57
218 M Control N/A 674 241 N/A N/A N/A 35
222 F Control N/A ND ND N/A N/A N/A 24
225 F Control N/A ND ND N/A N/A N/A 55
226 F Control N/A 1114 401 N/A N/A N/A 61
HIV ART-(n = 6) 217 M HIV+ No 307 1117 216000 9 yr None 39
224 F HIV+ No 238 1072 90000 3 yr None 39
207 F HIV+ No 151 385 55000 1.5 yr None 59
221 M HIV+ No 381 1188 50000 9 yr None 41
223 F HIV+ No 137 389 18000 1 yr None 30
212 M HIV+ No 525 873 9000 1.5y None 28
HIV + ART + (n = 6) 158 M HIV+ Yes 873 1302 UD 23 yr 20 yr 58
166 M HIV+ Yes 540 1041 UD 13 yr 13 yr 53
205 F HIV+ Yes 1069 582 UD 15 yr 8 yr 61
208 F HIV+ Yes 322 311 UD 6 yr 3 yr 37
219 F HIV+ Yes 490 531 UD 6 yr 6 yr 44
228 M HIV+ Yes 368 582 UD 9 yr 9 yr 39

Clinical characteristics of study participants. * CD4+, CD8+ T cells/mL blood. HIV RNA copies/mL blood. ART = antiretroviral therapy, Tx = treatment.

Dang et al.

Dang et al. BMC Microbiology 2012 12:153   doi:10.1186/1471-2180-12-153

Open Data